Announces the results for the second quarter of the fiscal year ending December 2026. Net sales were 401 million yen (YoY +59.8%), operating loss was 954 million yen, and net loss attributable to owners of the parent for the interim period was 1,039 million yen. Full-year guidance: net sales of 720 million yen and net loss for the period of 20.9 billion yen, with -108.95 yen per share. Although the drug discovery business remains in deficit, the drug discovery support business is expanding in revenue and profitability. Capital policy includes fund-raising through exercise of stock acquisition rights and bond issuance. There is material uncertainty related to the continuation of the company as a going concern.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Karna Biotechnology, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4572-20260806-01.pdf","jir_short_summary":"Announces the results for the second quarter of the fiscal year ending December 2026. Net sales were 401 million yen (YoY +59.8%), operating loss was 954 million yen, and net loss attributable to owners of the parent for the interim period was 1,039 million yen. Full-year guidance: net sales of 720 million yen and net loss for the period of 20.9 billion yen, with -108.95 yen per share. Although the drug discovery business remains in deficit, the drug discovery support business is expanding in revenue and profitability. Capital policy includes fund-raising through exercise of stock acquisition rights and bond issuance. There is material uncertainty related to the continuation of the company as a going concern.","jir_summary":"### Overview of results\nWhile the drug discovery business continues progression across multiple pipelines and collaborations, the drug discovery support business is expanding revenue regionally, and the interim-period consolidated net sales reached 401 million yen, significantly higher year over year. Operating loss was 954 million yen, ordinary loss 1,005 million yen, and net loss attributable to owners of the parent for the interim period was 1,039 million yen. Full-year projections are net sales of 720 million yen and net loss of approximately 20.9 billion yen. Capital policies have been implemented to strengthen the financial base. There is material uncertainty regarding the assumption of a going concern.\n\n### Outlook and capital policy\nFor the full year ending December 2026, the full-year forecast is net sales of 720 million yen, with no reduction in both ordinary income and net loss attributable to owners of the parent, and net loss for the period is expected to be approximately 20.9 billion yen. On the financial front, funds are being secured through the issuance of two unsecured bonds, exercise of convertible bonds and stock acquisition rights, and other capital strengthening measures. As of the interim end, the company remains in a negative equity position, and future licensing revenue and licensing agreements may improve the financial position depending on the status of such contracts.","jir_financial_highlights":"Net sales: 401,154 (YoY +59.8%)\nOperating loss: -954,112 (YoY improvement (previous year \u25b31,052,841))\nNet loss attributable to owners of the parent for the interim period: -1,039,782 (YoY improvement (previous year \u25b31,056,054))\nTotal assets: 1,765,502 (Compared with previous consolidated fiscal year)\nEquity ratio: -23.9% (Previous term 25.1%)","jir_category":"","jir_hashtags":"#KarnaBiotechnology, #FinancialSummary, #DrugDiscoveryPipeline, #CapitalPolicy","jir_key_figures":"Net sales: 401,154 \u5343\u5186\nOperating loss: -954,112 \u5343\u5186\nNet loss attributable to owners of the parent for the interim period: -1,039,782 \u5343\u5186","jir_meta_title":"Karna Biotechnology Second Quarter Financial Summary | Net sales 401 million yen; Drug discovery support expanding; persistent going-concern uncertainty","jir_meta_description":"Summary of Karna Biotechnology's Q2 FY2026 financial summary. Net sales 401 million yen; drug discovery support is growing. Full-year guidance: net sales 720 million yen; net loss about 20.9 billion yen. Capital policy included funding measures to strengthen financial base. Going concern uncertainty remains.","jir_og_title":"Karna Biotechnology | Q2 Financial Summary","jir_og_description":"Summary of progress in drug discovery and drug discovery support, and financial status. Explains current going-concern issue and funding developments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-98107","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n